Low doses of ketazolam in <font color="blue">anxiety_2</font> <font color="blue">:_2</font> a double - blind , placebo - controlled study . 
<br>
<br> A multicenter , double - blind , between - patient trial comparing two doses of ketazolam ( 15 and 30 mg ) with placebo , each given once daily , in the evening , to 92 outpatients affected by <font color="blue">generalized_1</font> <font color="blue">anxiety_2</font> <font color="blue">disorders_1</font> for at least 1 month , was carried out . After 1-week washout period 47 patients were randomized to ketazolam 15 mg , and 45 to placebo for 15 days ( first period ) . At the end of this period , if the patient experienced a <font color="blue">decrease_1</font> <font color="blue">on_1</font> <font color="blue">the_1</font> <font color="blue">total_1</font> <font color="blue">Hamilton_1</font> <font color="blue">Anxiety_1</font> <font color="blue">Rating_1</font> <font color="blue">Scale_1</font> <font color="blue">(_1</font> <font color="blue">HAM_1</font> <font color="blue">-_1</font> <font color="blue">A_1</font> <font color="blue">)_1</font> of at least 25% of basal value , the treatment was kept unchanged for a further 15 days , otherwise 15 mg of ketazolam were added to the previous treatment ( second period ) . <font color="blue">Anxiety_2</font> was rated after 2 and 4 weeks with the <font color="blue">Italian_1</font> <font color="blue">HAM_1</font> <font color="blue">-_1</font> <font color="blue">A_1</font> <font color="blue">scale_1</font> and with a <font color="blue">4-point_1</font> <font color="blue">scale_1</font> <font color="blue">(_1</font> <font color="blue">patient_1</font> <font color="blue">'s_1</font> <font color="blue">assessment_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> Seventy - eight patients completed the first period and 75 the whole study . During the first period the <font color="blue">percentage_1</font> <font color="blue">of_1</font> <font color="blue">responders_1</font> was almost identical in both treatment groups , but during the second period a further <font color="blue">slight_1</font> <font color="blue">improvement_1</font> was observed in the early placebo responders , while the <font color="blue">HAM_2</font> <font color="blue">-_2</font> <font color="blue">A_2</font> <font color="blue">score_2</font> of patients on ketazolam continued to <font color="blue">improve_1</font> <font color="blue">significantly_1</font> ( p less than 0.01 ) throughout the study . Likewise a significant ( p less than 0.001 ) difference between treatments was observed , on the <font color="blue">4-point_1</font> <font color="blue">scale_1</font> <font color="blue">,_1</font> in the population as a whole ( end of first period ) as well as in responder patients ( end second period ) . <font color="blue">Tolerability_3</font> was good , except in 1 patient on placebo , who was withdrawn from the study because of <font color="blue">severe_1</font> <font color="blue">headache_2</font> <font color="blue">._2</font>